BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
BC Extra | May 18, 2018
Company News

Management tracks: Seattle Genetics, SurModics

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) said CMO Jonathan Drachman has stepped down. He is succeeded by Roger Dansey, who was therapeutic area head for late-stage oncology at Merck & Co. Inc. (NYSE:MRK). Medical...
BC Week In Review | Jun 23, 2014
Clinical News

Combo Dual Therapy Stent: Phase IV started

OrbusNeich said investigators began the open-label, international Phase IV REDUCE trial to compare the 3-month Combo Dual Therapy Stent vs. the standard 12-month Combo Dual Therapy Stent in about 1,500 patients with ACS. The Combo...
BC Week In Review | Apr 7, 2014
Clinical News

Combo Dual Therapy Stent: Completed postmarketing study enrollment

OrbusNeich completed enrollment of 1,000 patients in the European REMEDEE Registry study to evaluate the Combo Dual Therapy Stent with a clinical follow up of up to 5 years. The Combo Dual Therapy Stent, which...
BC Week In Review | Mar 3, 2014
Clinical News

Combo Dual Therapy Stent: Pivotal trial started

OrbusNeich began the single-blind, U.S. and Japanese pivotal HARMONEE trial to compare its Combo Dual Therapy Stent vs. an everolimus-eluting stent in 572 patients with ischemic coronary disease and NSTEMI. The trial comprises 3 cohorts....
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 9, 2013
Company News

SurModics drug delivery, diagnostic news

SurModics said it will restructure its executive leadership and corporate functions and realign its workforce to "better position it for long-term growth." The restructuring will eliminate 7 positions (6%) and reduce headcount to 115. SurModics...
BC Week In Review | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

The open-label, Australian pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte paclitaxel-eluting...
BC Week In Review | Feb 11, 2013
Financial News

SurModics financial update

SurModics said its board authorized the repurchase of up to $10 million of the company's stock. The authorization is in addition to $300,000 remaining under a previous share repurchase authorization. The company, which closed Friday...
Items per page:
1 - 10 of 69
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
BC Extra | May 18, 2018
Company News

Management tracks: Seattle Genetics, SurModics

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) said CMO Jonathan Drachman has stepped down. He is succeeded by Roger Dansey, who was therapeutic area head for late-stage oncology at Merck & Co. Inc. (NYSE:MRK). Medical...
BC Week In Review | Jun 23, 2014
Clinical News

Combo Dual Therapy Stent: Phase IV started

OrbusNeich said investigators began the open-label, international Phase IV REDUCE trial to compare the 3-month Combo Dual Therapy Stent vs. the standard 12-month Combo Dual Therapy Stent in about 1,500 patients with ACS. The Combo...
BC Week In Review | Apr 7, 2014
Clinical News

Combo Dual Therapy Stent: Completed postmarketing study enrollment

OrbusNeich completed enrollment of 1,000 patients in the European REMEDEE Registry study to evaluate the Combo Dual Therapy Stent with a clinical follow up of up to 5 years. The Combo Dual Therapy Stent, which...
BC Week In Review | Mar 3, 2014
Clinical News

Combo Dual Therapy Stent: Pivotal trial started

OrbusNeich began the single-blind, U.S. and Japanese pivotal HARMONEE trial to compare its Combo Dual Therapy Stent vs. an everolimus-eluting stent in 572 patients with ischemic coronary disease and NSTEMI. The trial comprises 3 cohorts....
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 9, 2013
Company News

SurModics drug delivery, diagnostic news

SurModics said it will restructure its executive leadership and corporate functions and realign its workforce to "better position it for long-term growth." The restructuring will eliminate 7 positions (6%) and reduce headcount to 115. SurModics...
BC Week In Review | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

The open-label, Australian pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte paclitaxel-eluting...
BC Week In Review | Feb 11, 2013
Financial News

SurModics financial update

SurModics said its board authorized the repurchase of up to $10 million of the company's stock. The authorization is in addition to $300,000 remaining under a previous share repurchase authorization. The company, which closed Friday...
Items per page:
1 - 10 of 69